Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Co-DiagnosticsHAM:C970 61 EV-to-EBIT is 0.03 as of Aug. 02, 2026, which is 73% below its 10-year median of 0.11. GuruFocus rates HAM:C970 with a GF Score™ of 61/100 and a GF Value™ of €8.04. The stock has 6 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Co-Diagnostics ranks better than 99.36% on this metric.
The historical rank and industry rank for Co-Diagnostics's EV-to-EBIT or its related term are showing as below:
HAM:C970'
s EV-to-EBIT Range Over the Past 10 Years
Min: -68.73 Med: 0.11 Max: 72.14
Current: 0.03
During the past 11 years, the highest EV-to-EBIT of Co-Diagnostics was 72.14. The lowest was -68.73. And the median was 0.11.
HAM:C970's EV-to-EBIT is ranked better than 99.36% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 18.85
vs HAM:C970: 0.03
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Co-Diagnostics's Enterprise Value for the quarter that ended in Mar. 2026 was €14.63 Mil.
Co-Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-27.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics EV-to-EBIT Related Terms
Co-Diagnostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Co-Diagnostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:C970 vs HSCS, NVNO, SINT: EV-to-EBIT Comparison
For the Medical Devices subindustry, Co-Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's EV-to-EBIT falls into.
Co-Diagnostics's current Enterprise Value is €-0.74 Mil.
Co-Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-27.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics (HAM:C970) has a EV-to-EBIT of 0.03 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Co-Diagnostics and its competitors. This is 73% below median its historical median of 0.11. According to the industry distribution chart, Co-Diagnostics ranks #3 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 0.59999999999999%.
Is Co-Diagnostics' EV-to-EBIT too high?
Co-Diagnostics' current EV-to-EBIT of 0.03 is 73% below median its 10-year median of 0.11. The Medical Devices & Instruments industry median EV-to-EBIT is 18.85. Co-Diagnostics' value of 0.03 is 99.8% below this industry median. Based on the distribution chart, Co-Diagnostics ranks #3 out of 470 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Co-Diagnostics has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' EV-to-EBIT compare to HSCS and NVNO?
According to the Medical Devices & Instruments industry distribution chart, Co-Diagnostics ranks #3 out of 470 companies for EV-to-EBIT. This places Co-Diagnostics in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.85. Co-Diagnostics' value of 0.03 is 99.8% below this benchmark. While the company's 10-year median is 0.11 vs. the industry median of 18.85, Co-Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.85, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Co-Diagnostics's current EV-to-EBIT of 0.03 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Co-Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Co-Diagnostics's current EV-to-EBIT is 0.03, which is 73% below median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current EV-to-EBIT of 0.03. The stock's GF Value™ is €8.04, compared to a current price of €5.55 — trading 31% below its estimated fair value. The current EV-to-EBIT is 0.03, which is 73% below median its 10-year median of 0.11 and 99.8% below the Medical Devices & Instruments industry median of 18.85. Co-Diagnostics' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current EV-to-EBIT is 0.03 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued.
The current stock price of €5.55 is trading 31% below its estimated GF Value™ of €8.04.
Key valuation signals for HAM:C970:
EV-to-EBIT: 0.03 (73% below median its 10-year median of 0.11)
GF Value™: €8.04 vs. price of €5.55 (31% below fair value)
Industry Position: 99.8% below the Medical Devices & Instruments median (#3 of 470)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
61GF Score
Get the complete analysis for HAM:C970
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 
